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Although the vasoactive properties of carbon monoxide (CO) have been extensively
studied, the mechanism by which CO mediates vasodilation is not completely
understood. Through-out published studies on CO mediated vasodilation there is
inconsistency on the type of K+-channels that are activated by CO releasing molecules
(CORMs). Since the vasorelaxation properties of enzyme triggered CORMs (ET-CORMs)
have not been studied thus far, we first assessed if ET-CORMs canmediate vasodilation of
small mesenteric arteries and subsequently addressed the role of soluble guanylate
cyclase (sGC) and that of K-channels herein. To this end, 3 different types of ET-
CORMs that either contain acetate (rac-1 and rac-4) or pivalate (rac-8) as ester
functionality, were tested ex vivo on methoxamine pre-contracted small rat mesenteric
arteries in a myograph setting. Pre-contracted mesenteric arteries strongly dilated upon
treatment with both types of acetate containing ET-CORMs (rac-1 and rac-4), while
treatment with the pivalate containing ET-CORM (rac-8) resulted in no vasodilation. Pre-
treatment of mesenteric arteries with the sGC inhibitor ODQ abolished rac-4 mediated
vasodilation, similar as for the known sGC activator SNP. Likewise, rac-4 mediated
vasodilation did not occur in KCL pretreated mesenteric arteries. Although mesenteric
arteries abundantly expressed a variety of K+-channels only Kv7 channels were found to be
of functional relevance for rac-4 mediated vasodilation. In conclusion the current results
identified Kv7 channels as the main channel by which rac-4 mediates vasodilation. In
keeping with the central role of Kv7 in the control of vascular tone and peripheral resistance
these promising ex-vivo data warrant further in vivo studies, particularly in models of
primary hypertension or cardiac diseases, to assess the potential use of ET-CORMs in
these diseases.
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INTRODUCTION
Carbon monoxide (CO), endogenously produced by heme
oxygenases (HO), is considered to be an important signaling
molecule participating in a variety of cellular functions
(Romanski et al., 2012a; Olas, 2014; Naito et al., 2016). The
interest for using CO as a potential therapeutic agent has
increased considerably in the past decade as a number of
in vitro and in vivo studies have corroborated the beneficial
effect of CO in a variety of disease models (Guo et al., 2004;
Musameh et al., 2007; Ferrándiz et al., 2008). Clinical trials to
assess the feasibility and safety of therapeutic CO inhalation have
been performed in patients with chronic obstructive pulmonary
disease (NCT00122694) (Bathoorn et al., 2007) and in patients
with sepsis-induced acute respiratory distress syndrome
(NCT02425579) (Fredenburgh et al., 2018; Mayr et al., 2005).
While in phase I clinical studies CO was applied in its gaseous
form, in recent years a number of different CO releasing
molecules (CORMs) have been synthesized and successfully
tested in in vitro and in vivo inflammation models. CORMs
release CO either spontaneously or require specific triggering
mechanisms. In order to deliver CO directly into cells and to gain
a better control over CO release, we have introduced so called
enzyme-triggered CORMs (ET-CORMs) (Romanski et al., 2011;
Romanski et al., 2012a; Romanski et al., 2013). ET-CORMs are
acyloxy-butadiene–Fe(CO)3 complexes that are relatively stable
under physiological conditions. Once intracellular, the ester
functionality of ET-CORMs is cleaved by hydrolytic enzymes
(e.g., esterases), resulting in the formation of labile dienol iron
carbonyl complexes that subsequently disintegrate under
oxidative conditions to release CO, ferric ions and the
corresponding enones (Romanski et al., 2011). CO release can
be influenced by the type and position of the ester substituent of
the ET-CORM as well as by the mother compound from which it
is derived (Romanski et al., 2013). This concept also allows the
design of protease specific CO release, thus paving avenues for the
implementation of cell specific CO delivery (Sitnikov et al., 2015).
The HO-1/CO system plays prominent biological roles in the
vasculature. CO is an often under-appreciated signaling molecule,
acting on a wide variety of signaling pathways that regulate
vasodilation (Koçer et al., 2018), inflammation (Ryter and
Choi, 2016) as well as angiogenesis (Choi et al., 2017). CO
administration in its gaseous form appears to reduce the
contractility of pre-contracted arteries which may prevent or
mitigate the occurrence of vasoconstrictor mediated spasm of
arterial grafts in coronary artery bypass surgery in a cGMP
dependent manner (Wang et al., 1997a; Achouh et al., 2005).
CO delivery via CORMs also has beneficial effects on the
vasculature, e.g., blunting of placental ischemia induced
hypertension (George et al., 2017) and improvement of
cerebrovascular dysfunction caused by neonatal seizures (Liu
et al., 2015). Yet, vessel relaxation mediated by gaseous CO or
CORM-2 may differ in their mode of action as suggested by
Decaluwé et al. (Decaluwé et al., 2012). They postulated that CO
relaxes vessels through activation of sGC and/or calcium-
activated K+-channels, while it seems that CORM-2 induced
vasodilatation much more depends on voltage-dependent
rather than calcium-activated K+-channels. Participation of
cGMP, potassium channels and nitric oxide (NO) has been
postulated in the vasodilatory properties of the water soluble
CORM-2 and CORM-3 (Al-Owais et al., 2017), yet the
involvement of NO has been questioned by others (Failli et al.,
2012; Alshehri et al., 2013). Because CO can cause concomitantly
activation and inhibition of NO synthase, it seems that CORMs
display context-dependent effects as they can directly dilate blood
vessels, but also block NO-induced vasorelaxation (Alshehri et al.,
2013).
Even though the role of K+-channels in CO mediated
vasorelaxation is widely accepted, there exists controversy on
the class of K+-channels by which this occurs. Whether different
CORMs activate different K+-channels or if differences in CO
mediated vasorelaxation are due to differences in the expression
level of K+-channels in different vessels remains to be addressed.
Based on the current understanding of the vasoactive properties
of CO and CORMs, this study underlies the hypothesis that ET-
CORMs are able to cause vasodilation of pre-contracted
resistance vessels in a sGC and K+-channel dependent
manner. The hypothesis was tested by studying vascular
responses of small rat mesenteric arteries ex-vivo.
MATERIALS AND METHODS
Drugs
Acyloxydiene complexes (ET-CORM) rac-1, rac-4 and rac-8were
synthesized as previously described (Romanski et al., 2011). Stock
solutions were prepared in dimethyl sulfoxide (DMSO) and
stored at −20°C. The parent ligand of rac-4, 2-cyclohexenone
was included to assess whether vascular activity was mediated by
released CO or by the by-products of rac-4 cleavage.
Methoxamine, acetylcholine (both dissolved in H2O), XE991
and glibenclamide (both dissolved in DMSO) were obtained
from Sigma. Iberiotoxin and DPO-1 were obtained from
Tocris (Wiesbaden-Norden-stadt, Germany). Stromatoxin
(dissolved in H2O) was obtained from Alomone Labs
(Jerusalem, Israel). BaCl2 (dissolved in H2O) was obtained
from Riedel-de-Haën (Seelze, Germany).
Animals
Adult, 8- to 12-week-old, male Wistar rats were obtained from
Janvier (France; RRID: RGD_13,508,588). The animals were
provided with food and water ad libitum and housed in a
room with a controlled temperature and a 12-h light-dark
cycle in IVC cages. The use of laboratory animals and all
procedures included in this study were in accordance with the
NIH Guide for the care and Use of Laboratory Animals. Approval
for the use of laboratory animals in this study was granted by a
governmental committee on animal welfare (I-17/17).
Vessel Preparation
Rats were sacrificed under CO2 narcosis by decapitation. The
mesentery was immediately removed and transferred to cold
(4°C) physiological salt solution (PSS) composed of (in mM):
NaCl 145; KCl 4.5; CaCl2 0.1; MgSO4 1.0; NaH2PO4 1.2; EDTA
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0.025; HEPES 5.0 (pH  7.4). Mesenteric arteries (∼150 μm
diameter and 2 mm long) were dissected and cleaned off fat
and connective tissue. Mesenteric artery rings were mounted in a
wire myograph (model 610M, Danish Myo Technology,
Denmark). The organ bath was filled with 5 ml PSS consisting
of (in mM) NaCl 120; NaHCO3 26; KCl 4.5; CaCl2 1.6; MgSO4
1.0; NaH2PO4 1.2; D-glucose 5.5; EDTA 0.025; HEPES 5.0, was
heated to 37°C, and continuously oxygenated with carbogen (95%
O2/5% CO2) to maintain pH at 7.4. In some experiments, the
endothelium of mesenteric artery rings was removed by
scratching the lumen of the vessel gently with a rat whisker.
The successful functional removal of the endothelium was
confirmed by the absence of acetylcholine-induced
vasodilation of 1 μmol/L methoxamine pre-contracted arteries.
Each mesenteric artery segment underwent a normalization
procedure before the experiment. In order to obtain optimal
responses of the vessels, the segments were stretched stepwise to a
diameter corresponding to 90% of the diameter the vessel would
have at a transmural pressure of 100 mmHg (13,3kPa) using the
Lab Chart DMT (Mulvany and Halpern, 1977) Normalization
module. All data acquisition and analysis were performed using
LabChart (AD Instruments, United States). Viability of the vessel
preparations was determined with methoxamine at 10 μM to test
smooth muscle cell function. All drugs were added to the bath
solution. Arterial tension is expressed as a percentage of the
steady-state tension (100%) generated by 10 μM methoxamine.
Gene Expression Analysis
Mesenteric arteries were isolated as described above, snap-
frozen in liquid nitrogen and stored at −80°C. Total RNA
isolation was performed using the RNeasy RNA isolation kit
according to the manufacturer’s instruction. Further
purification of RNA was performed according to the
protocol provided by the manufacturer. The quantity and
quality of the isolated RNA were controlled using an RNA
6000 nano kit (Agilent, Waldbronn, Germany). Only samples
with an integrity RIN value > 7.5 were used for further analysis.
Reverse transcription was performed using a high capacity
RNA-to-cDNA Kit (Applied Biosystems, Weiterstadt,
Germany). Real-time PCR was performed on potassium ion
channel genes in parallel using TaqMan microfluidic card
technology in a Viia7 thermocycler (ThermoFisher,
Darmstadt, Germany) with a maximum of 40 cycles. These
cards contained wells for specific channel genes and five
reference (housekeeping) genes. All TaqMan primers were
tested before by dilution experiments and used only when
amplification efficacies were close to 100%. Threshold
quantification cycles (Cq values) were obtained for each
gene delivered by the manufacturer’s Viia7 software and
further analyzed using the ArrayStudio software package
(Version 9, Omicsoft Corporation, Research Triangle Park,
NC, United States). The levels of gene expression were
obtained by subtracting first from the individual Cq values
a geometric average normalizing value of four reference genes,
namely B2M, Eif2b1, Gusb, and Ywhaz. Relative expression
was then calculated as potency of this difference in Cq with the
basis of 2.
Statistics
All data are presented as mean ± SEM (standard error of the
mean). The n-value given in the figures correspond to the number
of animals tested. Differences between concentration-response
relationships were tested by ANOVA for repeated measurements.
The confidence level p was set to 0.05.
RESULTS
Vascular Activities of Structurally Different
ET-CORMs
Since the positions of the ester functionality in ET-CORMs, as
well as the mother compound from which they are derived,
strongly influence their biological activity (Romanski et al.,
2013), we first tested three structural different ET-CORMs
(Figure 1) for vascular activity. The tested concentrations were
chosen on the basis of preliminary experiments assessing the
toxicity of these ET-CORMs. Pre-contracted mesenteric arteries
strongly dilated upon treatment with both types of acetate
containing ET-CORMs (rac-1, Figures 2A,B; rac-4, Figures
2C,D), while treatment with the pivalate containing ET-
CORM (rac-8) resulted in no vasodilation (Figures 2E,F). For
the former types of ET-CORMs vasodilation occurred
irrespective of the presence or absence of the endothelium
(Figures 2A–D). In order to focus on smooth muscle cell
signaling all further experiments have been performed on
endothelium-denuded vessels. Vasodilation appeared to be
transient for rac-1, particularly in denuded arteries, whereas
for rac-4 arteries remained dilated over the whole
observation time.
ET-CORM Mediated Vascular Activity Is
Guanylyl Cyclase Dependent
In as much as rac-4 was most effective in inducing vasodilation at
a relative low concentration compared to the other ET-CORMs
tested, subsequent experiments to delineate the underlying
mechanisms were only performed with rac-4. As shown in
Figure 3A, vasodilation by rac-4 occurred in a concentration-
dependent manner. To exclude that vasodilation was mediated
via the byproducts of rac-4 hydrolysis rather than CO, FeCl2,
FeCl3 and 2-cyclohexanone were applied to the vessels. None of
these compounds lead to vasodilation (Figures 3B,C), suggesting
that CO released from rac-4 is likely responsible for modulating
vascular tone. Pre-treatment of mesenteric arteries with the
guanylyl cyclase inhibitor ODQ abolished rac-4 mediated
vasodilation (Figure 3D), similar as for the known guanylyl
cyclase activator SNP (Figure 3E).
ET-CORM Mediated Vascular Activity Is
Mediated by Potassium Channels
In order to address whether rac-4-induced vasodilation is mediated
by potassium channels, mesenteric arteries were pre-treated with
50mM KCl. Under these conditions, the efflux of K+ through
potassium channels in smooth muscle cells is abolished due to a
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lack of driving force for the ions, thereby eliminating the
functionality of potassium channels. Rac-4 produced considerable
relaxation of methoxamine pre-contracted mesenteric arteries
(Figure 4A). An effect of rac-4 on KCl pre-contracted arteries
was not detected (Figure 4B), indicating an involvement of
potassium channels in the vasodilatory action of rac-4.
In subsequent experiments we sought to assess which
potassium channels were mediating rac-4-induced
FIGURE 1 | Chemical structure of the ET-CORMs rac-1, rac-4, and rac-8.
FIGURE 2 | Vascular activities of structurally different ET-CORMs on mesenteric arteries. (A) Effect of rac-1 (rac-1 2*10–4 M) and of DMSO (control) on vessel
tension induced by 10–6 M methoxamine in endothelium-intact arteries. (repeated measures ANOVA, n  5, p < 0.05). (B) Effect of rac-1 (rac-1 2*10–4 M) and of DMSO
(control) on vessel tension induced by 10–6 M methoxamine in endothelium-denuded arteries. (repeated measures ANOVA, n  5, p < 0.05). (C) Effect of rac-4 (rac-4
10–5 M) and of DMSO (control) on vessel tension induced by 10–6 Mmethoxamine in endothelium-intact arteries. (repeated measures ANOVA, n  5, p < 0.05). (D)
Effect of rac-4 (rac-4 10–5 M) and of DMSO (control) on vessel tension induced by 10–6 M methoxamine in endothelium-denuded arteries. (repeated measures ANOVA,
n  5, p < 0.05). (E) Effect of rac-8 (rac-8 2*10–4 M) and of DMSO (control) on vessel tension induced by 10–6 M methoxamine in endothelium-intact arteries. (repeated
measures ANOVA, n  5, p  0.60). (F) Effect of rac-8 (rac-8 2*10–4 M) and of DMSO (control) on vessel tension induced by 10–6 M methoxamine in endothelium-
denuded arteries. (repeated measures ANOVA, n  5, p  0.06).
Frontiers in Pharmacology | www.frontiersin.org September 2021 | Volume 12 | Article 7023924
Zhang et al. ET-CROM mediated vasorelaxation by KV7
vasodilation. To this end, we first determined gene expression
levels of various potassium channels in mesenteric arteries by
qPCR. As shown in Figure 5, Kv1 (KCNA), Kv2 (KCNB), Kv3
(KCNC), Kv7 (KCNQ), Kv11, Kir2, Kir6, BK (Kca1) and SK
(Kca2) channels are abundantly expressed in these arteries. Of
note, Kv3, Kv11, Kir2 and SK channels were not further explored
because of a lack of specific inhibitors or a lack of published data
suggesting their involvement in guanylyl cyclase-mediated
vasodilation. The contribution of the other potassium channels
to rac-4mediated vasodilation was studied using specific channel
inhibitors as depicted in Table 1.
Further, mesenteric arteries were pre-treated with different
combinations of potassium channel inhibitors leaving only Kir2,
Kir6, BK or Kv channels, respectively available (Table 1). When
compared to the effect of its solvent DMSO, rac-4 induced only
vasodilation when Kv channels were not inhibited
(Figures 6A–D).
In order to identify the Kv channel subtype involved,
mesenteric arteries were pre-treated with different
combinations of potassium channel inhibitors leaving only
Kv1, Kv2 or Kv7 channels available (Table 2). Rac-4 did not
induce vasodilation compared to the effects of its solvent
DMSO when only Kv1 (Figure 7A) or only Kv2
(Figure 7B) channels were available. In contrast, when only
Kv7 channels were left available rac-4 was able to dilate the
vessels (Figure 7C). In line with this, inhibition of Kv7
FIGURE 3 | Dilation of mesenteric arteries induced by rac-4 is guanylyl cyclase dependent. (A)Methoxamin-induced contraction in the absence of any substances
(Control) and in the presence of different concentrations of rac-4 (10–6 M, 3*10–6 M, 10–5 M). (repeated measures ANOVA, n  6, p < 0.05, particular comparisons
indicated in legend). (B) Methoxamin-induced contraction in the absence of any substances (Control) and in the presence of 3*10–6 M FeCl2 and FeCl3, respectively.
(repeatedmeasures ANOVA, n  6, p  0.68 and p  0.53 for FeCl2 and FeCl3, respectively). (C)Methoxamin-induced contraction in the absence of any substances
(Control) and in the presence of 3*10–6 M 2-cyclohexenone. (repeated measures ANOVA, n  5, p  0.77). (D) Methoxamin-induced contraction in the absence of any
substances (Control), in the presence of 10–5 M ODQ, in the presence of 3*10–6 M rac-4 and in the presence of the combination of ODQ and rac-4. (repeated measures
ANOVA, n  6, Control vs rac-4: p < 0.05; Control vs ODQ: p  0.79; ODQ vs ODQ + rac-4: p  0.26). (E) Methoxamin-induced contraction in the absence of any
substances (Control), in the presence of 10–5 M ODQ, in the presence of 10–6 M SNP and in the presence of the combination of ODQ and SNP. (repeated measures
ANOVA, n  6, Control vs SNP: p < 0.05; Control vs ODQ: p  0.77; ODQ vs ODQ + SNP: p  0.90).
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channels only by XE991 completely abolished rac-4 induced
vasodilation (Figure 7D).
DISCUSSION
Carbon monoxide (CO) is an autocrine and paracrine vasodilator
that can regulate tone in resistance vessels throughout the body
(Leffler et al., 1999). While it has been suggested that gaseous CO
mediates vasodilation through the activation of large-
conductance Ca2+-activated potassium (BKCa) channels as well
as sGC present in arterial smooth muscle cells (Wang et al.,
1997b; Jaggar et al., 2005), the role of the former has been
questioned when applying the CO-donor CORM-2 (Wang
et al., 1997b) but not CORM-A1 (Ryan et al., 2006) on
femoral or renal interlobar arteries respectively. Whether this
is due to differential activation of K+-channels by different
CORMs or due to differences in the expression level of K+-
channels in different vessels is still elusive. The cytoprotective -,
anti-inflammatory - and CO releasing properties of ET-CORMs
FIGURE 4 | Dilation of mesenteric arteries induced by rac-4 is K-channel dependent. (A) Effect of rac-4 (rac-4 3*10–6 M) and of DMSO (control) on vessel tension
induced by 10–6 M methoxamine. (repeated measures ANOVA, n  6, p < 0.05). (B) Effect of rac-4 (rac-4 3*10–6 M) and of DMSO (control) on vessel tension induced by
50 mM KCl. (repeated measures ANOVA, n  8, p  0.14).
FIGURE 5 |mRNA expression of K-channels in mesenteric arteries. Relative expression of K (+)-channels assessed by realtime PCRwith Taqman primers in intact
mesenteric arteries. Normalized was performed as described in the method sections relative to the expression of five reference (housekeeping) genes, B2M, Eif2b1,
Gusb, Myh11, and Ywhaz (n  8).
TABLE 1 | combination of potassium channel inhibitors used for leaving only a particular channel available.
Nr. Combination of potassium channel inhibitorsa Available channel Blocked channel
1 Iberiotoxin, XE991, DPO-1, STTX, Glibenclamid Kir2 BK, Kv7, Kv1, Kv2, Kir6
2 Iberiotoxin, XE991, DPO-1, STTX, BaCl2 Kir6 BK, Kv7, Kv1, Kv2, Kir2
3 XE991, DPO-1, STTX, Glibenclamid, BaCl2 BK Kv7, Kv1, Kv2, Kir6, Kir2
4 Iberiotoxin, Glibenclamid, BaCl2 Kv BK, Kir6, Kir2
aConcentration used: Iberiotoxin (BK) 0.1 µM (Galvez et al., 1990); XE991 (Kv7) 3 µM (Greenwood and Ohya, 2009; Zavaritskaya et al., 2020); DPO-1 (Kv1) 1 µM (Lagrutta et al., 2006;
Tsvetkov et al., 2016); Stromatoxin (STTX) (Kv2) 0.1 µM (Escoubas et al., 2002); BaCl2 (Kir2) 30 µM (Schubert et al., 2004); Glibenclamide (Kir6) 1 µM (Schubert et al., 1997).
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have been extensively studied (Ryan et al., 2006; Romanski et al.,
2013; Stamellou et al., 2014), yet if ET-CORMs also are vasoactive
on resistance vessels remains to be addressed. Based on the
current understanding of the vasoactive properties of CO and
CORMs, this study underlies the hypothesis that ET-CORMs are
able to cause vasodilation of pre-contracted resistance vessels in a
sGC and K+-channel dependent manner. The main findings of
this study are as follows. 1) Pre-contracted mesenteric arteries
strongly dilate upon treatment with both types of acetate
containing ET-CORMs (rac-1 and rac-4), while treatment with
the pivalate containing ET-CORM (rac-8) resulted in no
vasodilation. 2) Pre-treatment of mesenteric arteries with the
sGC inhibitor ODQ abolished rac-4 mediated vasodilation,
similar as for the known sGC activator SNP. 3) A variety of
K+-channels are expressed in mesenteric arteries. The relative
expression of each largely differs. 4) rac-4 mediated vasodilation
occurs when only Kv7 channels are available and is blocked by the
Kv7 inhibitor XE991. This suggests that Kv7 channels are the
main potassium channels by which rac-4mediates vasodilation in
the vessels studied.
In previous studies, we revealed that the anti-inflammatory
and cytoprotective properties of ET-CORMs strongly depend on
their chemical structure, more specifically on the mother
compound they are derived from and the type and position of
the ester functionality that they harbor (Stamellou et al., 2014). In
the present study, we show that this also holds true for the
FIGURE 6 | Dilation of mesenteric arteries induced by rac-4 is Kv-channel dependent. (A) Effect of rac-4 (rac-4 3*10–6 M) and of DMSO (control) on vessel tension
induced by methoxamine together with a mixture of K-channel blockers (10−7 M Iberiotoxin, 3*10−6 M XE991, 10–6 M DPO-1, 10−7 M stromatoxin, 10−6 M
glibenclamide) leaving only Kir2 channels available. Of note, both treatments reached the same level of vessel tension. (repeated measures ANOVA: n  8; p  0.09). (B)
Effect of rac-4 (rac-4 3*10–6 M) and of DMSO (control) on vessel tension induced by methoxamine together with a mixture of K-channel blockers (10−7 M
Iberiotoxin, 3*10−6 M XE991, 10–6 MDPO-1, 10−7 M stromatoxin, 3*10−5 M BaCl2) leaving only Kir6 channels available. Of note, both treatments reached the same level
of vessel tension. (repeated measures ANOVA: n  8; p  0.07). (C) Effect of rac-4 (rac-4 3*10–6 M) and of DMSO (control) on vessel tension induced by methoxamine
together with a mixture of K-channel blockers (3*10−6 M XE991, 10–6 M DPO-1, 10−7 M stromatoxin, 3*10−5 M BaCl2, 10
−6 M glibenclamide) leaving only BK channels
available. Of note, both treatments reached the same level of vessel tension. (repeated measures ANOVA: n  7; p  0.28). (D) Effect of rac-4 (rac-4 3*10–6 M) and of
DMSO (control) on vessel tension induced by methoxamine together with a mixture of K-channel blockers (10−7 M Iberiotoxin, 3*10−5 M BaCl2, 10
−6 M glibenclamide)
leaving only Kv channels available. Of note, both treatments reached the same level of vessel tension. (repeated measures ANOVA: n  7; p < 0.05).
TABLE 2 | Combination of Kv channel inhibitors used for leaving only a particular channel available.
Nr. Combination of potassium channel inhibitorsa Available channel Blocked channel
1 Iberiotoxin, XE991, STTX, Glibenclamid, BaCl2 Kv1 BK, Kv7, Kv2, Kir6, Kir2
2 Iberiotoxin, XE991, DPO-1, Glibenclamid, BaCl2 Kv2 BK, Kv7, Kv1, Kir6, Kir2
3 Iberiotoxin, DPO-1, STTX, Glibenclamid, BaCl2 Kv7 BK, Kv1, Kv2, Kir6, Kir2
4 XE991 BK, Kv1, Kv2, Kir6, Kir2 Kv7
aConcentration used: Iberiotoxin (BK) 0.1 µM (Galvez et al., 1990); XE991 (Kv7) 3 µM (Greenwood and Ohya, 2009; Zavaritskaya et al., 2020); DPO-1 (Kv1) 1 µM (Lagrutta et al., 2006;
Tsvetkov et al., 2016); Stromatoxin (STTX) (Kv2) 0.1 µM (Escoubas et al., 2002); BaCl2 (Kir2) 30 µM (Schubert et al., 2004); Glibenclamide (Kir6) 1 µM (Schubert et al., 1997).
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vasorelaxation properties of ET-CORMs. The efficacy of the
acetate containing ET-CORMs, rac-1 and rac-4 was similar as
reported for the inhibition of VCAM-1 (Romanski et al., 2013;
Stamellou et al., 2014), with rac-4 being more effective compared
to rac-1. This correlates with the slower release of CO from rac-1
(Romanski et al., 2012b). In contrast to the acetate containing ET-
CORMs, rac-8 was not able to cause vasodilation of pre-
contracted mesenteric arteries, an unexpected finding based on
previous published biological properties that were similar for rac-
1 and rac-8. However, it should be emphasized that previous
experiments with rac-8 were performed in human cells, which,
compared to rat mesenteric arteries, may express different types
of esterase enzymes for hydrolysis of the pivalate ester
functionality. Moreover, uptake and hydrolysis of rac-8 by
mesenteric arteries may require more time than the 30-min
time frame in which vasodilation was recorded. Previous
publications have indeed demonstrated differences in
hydrolysis efficiencies of acetate and pivalate propanolol
prodrugs (Takahashi et al., 1995) and acyloxy nitroso
compounds (Shoman et al., 2011) Likewise, the finding that
pig liver esterase-induced CO release from pivalate containing
ET-CORMs is much slower compared to that of the
corresponding acetate containing ET-CORMs (Romanski et al.,
2012b) corroborates the current results obtained with rac-1, rac-4
and rac-8. It should also be noted that the cytoprotective
properties of ET-CORMs we reported previously were
attributed to the inhibition of the NFκB–and activation of the
Nrf2-Keap1 pathways (Ryan et al., 2006). These pathways are not
involved in vasorelaxation.
Our study demonstrates that rac-4 mediates vasorelaxation in
mesenteric arteries irrespective of a disrupted endothelium. In
contrast, Alshehri et al. (Alshehri et al., 2013) reported that
CORM-3 mediated vasorelaxation is partly endothelium
dependent in the largest conduit vessel of the organism, the
aorta. Differences in the vessel studied, concentrations used
(100 µM vs. in 10 μM, CORM-3 vs. rac-4) and intrinsic
properties of the CORMs may underlie this discrepancy. In line
with our current findings, most studies, including the study of
Alshehri et al. (Alshehri et al., 2013), report that CO and CORM
mediated vasorelaxation involves activation of the sGC (De Backer
and Lefebvre, 2007; van der Sterren et al., 2011; Magierowska et al.,
2019), even though sGC binds CO only with limited affinity
(Martin et al., 2006). There are also studies however in which
sGC did not participate in CO mediated vasorelaxation. As such
ODQ did not inhibit, but rather potentiated endothelium
independent relaxation by CORM-3 in WKY rat aorta rings
(Achouh et al., 2005). Also, in the study of Decaluwé K et al.
(Wang et al., 1997b) it was reported that vasorelaxation by gaseous
FIGURE 7 |Dilation of mesenteric arteries induced by rac-4 is Kv7-channel dependent. (A) Effect of rac-4 (rac-4 3*10–6 M) and of DMSO (control) on vessel tension
induced by methoxamine together with a mixture of K-channel blockers (10−7 M Iberiotoxin, 3*10−6 M XE991, 10−7 M stromatoxin, 3*10−5 M BaCl2, 10
−6 M
glibenclamide) leaving only Kv1 channels available. Of note, both treatments reached the same level of vessel tension. (repeated measures ANOVA: n  6; p  0.63). (B)
Effect of rac-4 (rac-4 3*10–6 M) and of DMSO (control) on vessel tension induced by methoxamine together with a mixture of K-channel blockers (10−7 M
Iberiotoxin, 3*10−6 M XE991, 10–6 M DPO-1, 3*10−5 M BaCl2, 10
−6 M glibenclamide) leaving only Kv2 channels available. Of note, both treatments reached the same
level of vessel tension. (repeated measures ANOVA: n  7; p  0.09). (C) Effect of rac-4 (rac-4 3*10–6 M) and of DMSO (control) on vessel tension induced by
methoxamine together with a mixture of K-channel (10−7 M Iberiotoxin, 10–6 M DPO-1, 10−7 M stromatoxin, 3*10−5 M BaCl2, 10
−6 M glibenclamide) leaving only Kv7
channels available. Of note, both treatments reached the same level of vessel tension. (repeated measures ANOVA: n  10; p < 0.05). (D) Effect of rac-4 (rac-4 3*10–6 M)
and of DMSO (control) on vessel tension induced by methoxamine together with 3*10−6 M XE991 blocking only Kv7 channels. Of note, both treatments reached the
same level of vessel tension. (repeated measures ANOVA: n  6; p  0.42).
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CO strongly depends on sGC activation, while ODQ had no effect
on CORM-2 induced relaxations of mice femoral arteries.
The proficiency of CO to regulate a variety of ion channels, e.g.,
calcium-activated K+ (BKCa) channels (Jaggar et al., 2005), voltage-
activated K+ (Kv) channels (Dallas et al., 2011), and Ca2+ channels
(Duckles et al., 2015), has been demonstrated in many studies and
reflects the pluripotency of CO to participate in numerous
physiological processes and pathologies. Likewise, the
involvement of K+-channels in CO mediated vasorelaxation is
unequivocally reported, albeit that there is ambiguity with respect
to the class of K+-channels that are supposedly involved. While a
number of studies have suggested an association between HO and
BKCa channels (Williams et al., 2004; Kooli et al., 2008) or their
activation by CO (Wang et al., 1997a; Jaggar et al., 2002; Yi et al.,
2010), other studies have postulated a role for voltage-gated K+-
channels (Kv1.5, Kv11.1) (Dong et al., 2007). Our data on rac-4
mediated vasorelaxation do not support the involvement of BKCa
channels, but insteadwe observed that rac-4 induced only significant
vasodilation when Kv7 channels were not inhibited. Failure of rac-4
to activate BKCa channels is unlikely due to differences in the relative
expression between BKCa (Kca1) and Kv7 (KCNQ) as the mRNA
expression of the former was even slightly higher. Themechanism by
whichCO affects BKCa is ambiguously discussed (Wang et al., 1997b;
Jaggar et al., 2005) (De Backer and Lefebvre, 2007). In the studies of
Jaggar et al. (Jaggar et al., 2005) CO activates BKCa channels by
binding to channel-bound heme, which alters the interaction
between heme and the conserved heme-binding domain of the
channel. Their data corroborate previous findings of Wang et al.
(Wang et al., 1997b) who showed that the effect of gaseous CO on
KCa channels was not mediated by cGMP, but contradict the
findings of De Backer et al. (De Backer and Lefebvre, 2007) in
which CO mediated relaxation in circular smooth muscle strips of
the murine gastric fundus and jejunum was sGC and BKCa channel
dependent. Due to different releasing mechanisms described for
CORMs it is conceivable that steady-state intracellular CO
concentrations will be reached faster by gaseous CO than by
CORMs. This is particularly the case for ET-CORMs, which
require further intra-cellular processing before CO is released
(Romanski et al., 2012a). Hence, higher CO concentrations may
favor the interaction with heme in BKCa, while the relatively small
amount of CO released for rac-4 within the timeframe of the
experiment may not suffice to activate BKCa channels. We
postulate that rac-4 stimulates sGC, resulting in the activation of
cGMP-dependent protein kinase (PKG) that subsequently
phosphorylates and activates Kv7 channels. With the exception of
Kv7.1 a conserved PKG phosphorylation site, i.e., KFKE (T/S)LRPY,
is present in all other Kv7 members. PKG mediated Threonine or
Serine phosphorylation of this site was predicted by the NetPhos 3.1
server. Assessment of cGMP and phosphorylation of Kv7 in
mesenteric arteries is warranted to strengthen this assumption.
Ruthenium-containing carbonyl complexes such as
tricabonyldichlororuthenium (II) dimer (CORM-2) or [Ru(CO)
3Cl (glycinate)] (CORM-3) can activate K+-channels directly and
independent of CO release (Dong et al., 2007; Hou et al., 2008;
Williams et al., 2008; Riddle andWalker, 2012; Gessner et al., 2017)
Hydrolysis of rac-4 results in the generation of CO, acetic acid, 2-
cyclohexanone and Fe2+/3+ in amolar ratio of 3:1 (CO: break-down
product). Although our study does not provide formal proof that
rac-4mediated vasorelaxation exclusively involves CO, none of the
break-down products were able to mediate vasodilation of pre-
contracted mesenteric arteries. It should be emphasized however,
that hydrolysis of rac-4 occurs intra-cellular, yet it is not clear to
what extent each of the break-down products are taken up by the
mesenteric arteries when applied in the myograph.
In conclusion our current study has clearly demonstrated that
the acetate containing ET-CORMs can mediate vasorelaxation of
small mesenteric arteries in a sGC and Kv7 dependent manner.
Both in rodents and human Kv7 proteins are expressed in the
smooth muscle layer of visceral arteries (Ng et al., 2011; Haick
and Byron, 2016), where they regulate contractility and vascular
resistance. If all Kv7 subtypes are activated by rac-4 remains to be
addressed. While our study uses an ex-vivo model for assessing
vascular responses, in vivo regulation of vascular tone is more
complex. Yet, in keeping with the potential role of Kv7 channels
in cardiovascular disease (Brenyo et al., 2012), hypertension (Carr
et al., 2016), obesity and diabetes (Yamagata et al., 2011), these
promising ex-vivo data warrant further in vivo studies in relevant
disease models to assess the therapeutic potential of ET-CORMs.
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